Back to Search Start Over

Transcranial Magnetic Stimulation for Long-Term Smoking Cessation: Preliminary Examination of Delay Discounting as a Therapeutic Target and the Effects of Intensity and Duration

Authors :
Alina Shevorykin
Ellen Carl
Martin C. Mahoney
Colleen A. Hanlon
Amylynn Liskiewicz
Cheryl Rivard
Ronald Alberico
Ahmed Belal
Lindsey Bensch
Darian Vantucci
Hannah Thorner
Matthew Marion
Warren K. Bickel
Christine E. Sheffer
Source :
Frontiers in Human Neuroscience, Vol 16 (2022)
Publication Year :
2022
Publisher :
Frontiers Media S.A., 2022.

Abstract

BackgroundRepetitive transcranial magnetic stimulation (rTMS) is a novel treatment for smoking cessation and delay discounting rate is novel therapeutic target. Research to determine optimal therapeutic targets and dosing parameters for long-term smoking cessation is needed. Due to potential biases and confounds introduced by the COVID-19 pandemic, we report preliminary results from an ongoing study among participants who reached study end prior to the pandemic.MethodsIn a 3 × 2 randomized factorial design, participants (n = 23) received 900 pulses of 20 Hz rTMS to the left dorsolateral prefrontal cortex (PFC) in one of three Durations (8, 12, or 16 days of stimulation) and two Intensities (1 or 2 sessions per day). We examined direction and magnitude of the effect sizes on latency to relapse, 6-month point-prevalence abstinence rates, research burden, and delay discounting rates.ResultsA large effect size was found for Duration and a medium for Intensity for latency to relapse. Increasing Duration increased the odds of abstinence 7–8-fold while increasing Intensity doubled the odds of abstinence. A large effect size was found for Duration, a small for Intensity for delay discounting rate. Increasing Duration and Intensity had a small effect on participant burden.ConclusionFindings provide preliminary support for delay discounting as a therapeutic target and for increasing Duration and Intensity to achieve larger effect sizes for long-term smoking cessation and will provide a pre-pandemic comparison for data collected during the pandemic.Clinical Trial Registration[www.ClinicalTrials.gov], identifier [NCT03865472].

Details

Language :
English
ISSN :
16625161
Volume :
16
Database :
Directory of Open Access Journals
Journal :
Frontiers in Human Neuroscience
Publication Type :
Academic Journal
Accession number :
edsdoj.8981e39c513748dca15511c2386478ff
Document Type :
article
Full Text :
https://doi.org/10.3389/fnhum.2022.920383